Gene · 4241
Papers1,420
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 1,420
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A multi-omics study reveals molecular characteristics and therapeutic targets of salidroside in reducing TGF-β2-induced ECM expression. | Exp Eye Res | 2025 | 40216062 | PubTator, text mining | PubMed |
| A genome-scale drug discovery pipeline uncovers new therapeutic targets and a unique p97 allosteric binding site in Schistosoma mansoni. | bioRxiv | 2025 | 40161785 | PubTator, text mining | PubMed |
| ALS-related p97 R155H mutation disrupts lysophagy in iPSC-derived motor neurons. | Stem Cell Reports | 2025 | 40157354 | PubTator, text mining | PubMed |
| Analysis of ferritinophagy-related genes associated with the prognosis and regulatory mechanisms in non-small cell lung cancer. | Front Med (Lausanne) | 2025 | 40124684 | PubTator, text mining | PubMed |
| Omics data integration analysis identified new biological insights into chronic antibody-mediated rejection (CAMR). | J Transl Med | 2025 | 39979925 | PubTator, text mining | PubMed |
| Integrated Computational Analysis Reveals Early Genetic and Epigenetic AML Susceptibility Biomarkers in Benzene-Exposed Workers. | Int J Mol Sci | 2025 | 39940906 | PubTator, text mining | PubMed |
| Analysis of the progression of cervical cancer in a low-and-middle-income country: From pre-malignancy to invasive disease. | Tumour Virus Res | 2025 | 39672307 | PubTator, text mining | PubMed |
| Mechanisms and regulation of substrate degradation by the 26S proteasome. | Nat Rev Mol Cell Biol | 2025 | 39362999 | PubTator, text mining | PubMed |
| Unlocking the potential of melanotransferrin (CD228): implications for targeted drug development and novel therapeutic avenues. | Expert Opin Ther Targets | 2024 | 39676256 | PubTator, text mining | PubMed |
| Correction: Arsenic trioxide and p97 inhibitor synergize against acute myeloid leukemia by targeting nascent polypeptides and activating the ZAKα-JNK pathway. | Cancer Gene Ther | 2024 | 39433907 | PubTator, text mining | PubMed |
| Mystery of Melanotransferrin in Melanoma. | J Invest Dermatol | 2024 | 39283284 | PubTator, text mining | PubMed |
| Molecular Signatures of CB-6644 Inhibition of the RUVBL1/2 Complex in Multiple Myeloma. | Int J Mol Sci | 2024 | 39201707 | PubTator, text mining | PubMed |
| mRNA expression insights: Unraveling the relationship between COPD and lung cancer. | J Gene Med | 2024 | 39183385 | PubTator, text mining | PubMed |
| Coordination of transcription-coupled repair and repair-independent release of lesion-stalled RNA polymerase II. | Nat Commun | 2024 | 39154022 | PubTator, text mining | PubMed |
| Arsenic trioxide and p97 inhibitor synergize against acute myeloid leukemia by targeting nascent polypeptides and activating the ZAKα-JNK pathway. | Cancer Gene Ther | 2024 | 39122830 | PubTator, text mining | PubMed |
| Targeting p97-Npl4 interaction inhibits tumor Treg cell development to enhance tumor immunity. | Nat Immunol | 2024 | 39107403 | PubTator, text mining | PubMed |
| A modular DNA origami nanocompartment for engineering a cell-free, protein unfolding and degradation pathway. | Nat Nanotechnol | 2024 | 39075293 | PubTator, text mining | PubMed |
| Senataxin mediates R-loop resolution on HPV episomes. | J Virol | 2024 | 39046232 | PubTator, text mining | PubMed |
| Covalent binding of withanolides to cysteines of protein targets. | Biochem Pharmacol | 2024 | 38969301 | PubTator, text mining | PubMed |
| A non-symmetrical p97 conformation initiates a multistep recruitment of Ufd1/Npl4. | iScience | 2024 | 38947518 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4241/papers?page=3